Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT03226249
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
- NCT03226249 ↗
- Unknown
- Northwestern University
- Focused
We haven't built an HCP commentary report on NCT03226249 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03226249 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Classical Hodgkin Lymphoma; Lymphocyte-Depleted Classical Hodgkin Lymphoma; Lymphocyte-Rich Classical Hodgkin Lymphoma; Mixed Cellularity Classical Hodgkin Lymphoma; Nodular Sclerosis Classical Hodgkin Lymphoma
- Interventions
- Computed Tomography; Dacarbazine; Doxorubicin Hydrochloride; Fludeoxyglucose F-18; Laboratory Biomarker Analysis; Pembrolizumab; Positron Emission Tomography; Vinblastine Sulfate
- Arms
- Treatment (FDG-PET/CT, pembrolizumab, chemotherapy) · Experimental
- Enrollment
- 30
- Primary outcomes
- Complete Response (CR) With Pembrolizumab Treatment Alone
- Sponsor
- Northwestern University with National Cancer Institute (NCI), Merck Sharp & Dohme LLC
- Start
- Nov 9, 2017
- Primary completion
- May 17, 2019
- Results posted
- Yes
- Registry record
- NCT03226249 · updated Jun 2, 2023
Publications
linked from the registry- Kreuzberger N, Goldkuhle M, von Tresckow B, Kobe C, Sickinger MT, Monsef I, Skoetz N. Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma. Cochrane Database Syst Rev. 2025 Mar 26;3(3):CD010533. doi: 10.1002/14651858.CD010533.pub3. PubMed 40135712
- Allen PB, Lu X, Chen Q, O'Shea K, Chmiel JS, Slonim LB, Sukhanova M, Savas H, Evens AM, Advani R, Pro B, Karmali R, Palmer B, Bayer RA, Eisner RM, Mou E, Dillehay G, Gordon LI, Winter JN. Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Adv. 2023 Jun 27;7(12):2670-2676. doi: 10.1182/bloodadvances.2022008116. PubMed 36083129
- Allen PB, Savas H, Evens AM, Advani RH, Palmer B, Pro B, Karmali R, Mou E, Bearden J, Dillehay G, Bayer RA, Eisner RM, Chmiel JS, O'Shea K, Gordon LI, Winter JN. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood. 2021 Mar 11;137(10):1318-1326. doi: 10.1182/blood.2020007400. PubMed 32992341